Jacobs University and IME signed MoU

Jacobs University Bremen and the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, today announce their intention to set up a new strategic collaboration to establish joint research projects in the area of antibiotic drug discovery and promote the exchange of students, researchers and educators between the institutions.
Through this partnership, Fraunhofer IME will offer Jacobs University undergraduate students the opportunity to be actively involved in Fraunhofer IME’s scientific research agenda, either by enrolling in an internship program or by completing a research project as part of their Bachelor thesis studies. Active involvement of undergraduates in ongoing interdisciplinary research projects at Fraunhofer IME will support the scientific education of the students, and help them to establish future careers in the pharmaceu­tical and biotechnology industries. The Fraunhofer IME offers internships in a wide range of experimental and computational disciplines within the economically important Life Science sector, with a focus on drug discovery and development. Doctoral students working at Fraunhofer IME in Hamburg will also be enrolled in PhD programs of Jacobs University. As part of the collaboration, Fraunhofer IME will share its know-how in applied research and modern drug discovery methods. Experienced scientists from Fraunhofer IME in Hamburg will offer courses, lectures and seminars at Jacobs University, in particular as an integral part of the undergraduate Bachelors program, Medicinal Chemistry and Chemical Biology. Fraunhofer IME and Jacobs University also intend to exchange scientific staff, in order to share the complementary expertise existing at both institutions. In future, both partners envisage jointly recruiting scientists for shared positions, to help efficiently advance common research projects, particularly those focused on discovering the next generation of treatments against bacterial infections. The potent strategic collaboration will build upon a pre-existing 5-year record of cooperation involving Jacobs and the Fraunhofer IME, which has already attracted substantial funding under the European Union framework programs. Prof. Werner Nau, Dean of Jacobs University Bremen: “The strategic partnership with the Fraunhofer IME will strengthen our teaching and research in the area Health with a focus on bioactive substances. Our students will get the opportunity to participate in challenging projects which are of prime interest to the pharmaceuti­cal industry.” Dr. Björn Windshügel, Head of Structure-based drug design at Fraunhofer IME: “We are very excited about this collaboration as it will not only advance antibacterial drug discovery research in Northern Germany but also offers various opportunities for joint education of students.“ Press Release Fraunhofer IME ScreeningPort from June, 11th 2018

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …